Microbot Medical Inc.
MBOT
$1.54
$0.106.94%
| Weiss Ratings | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.73 | |||
| Price History | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 10.79% | |||
| 30-Day Total Return | -16.30% | |||
| 60-Day Total Return | 54.00% | |||
| 90-Day Total Return | 62.77% | |||
| Year to Date Total Return | 35.09% | |||
| 1-Year Total Return | 38.74% | |||
| 2-Year Total Return | -29.03% | |||
| 3-Year Total Return | -68.83% | |||
| 5-Year Total Return | -65.16% | |||
| 52-Week High % Change | -54.44% | |||
| 52-Week Low % Change | 87.80% | |||
| Price | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.38 | |||
| 52-Week Low Price | $0.82 | |||
| 52-Week Low Price (Date) | Sep 05, 2024 | |||
| 52-Week High Price (Date) | Jan 06, 2025 | |||
| Valuation | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 53.51M | |||
| Enterprise Value | 49.26M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.80 | |||
| Earnings Per Share Growth | -33.86% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 6.73 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.54 | |||
| Enterprise Value/EBITDA (TTM) | -4.85 | |||
| Enterprise Value/EBIT | -4.80 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 16.47M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 875 3605 | |||
| Address | 288 Grove Street Braintree, MA 02184 | |||
| Website | microbotmedical.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -91.01% | |||
| Return on Equity | -- | |||
| Income Statement | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -10.16M | |||
| EBIT (TTM) | -10.26M | |||
| Net Income (TTM) | -11.21M | |||
| Net Income Avl. to Common (TTM) | -11.21M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -31.44% | |||
| EPS Diluted (TTM) | -0.80 | |||
| EPS Diluted Growth (Q YOY) | 6.56% | |||
| Balance Sheet | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 4.34M | |||
| Cash Per Share (Q) | $0.26 | |||
| Total Current Assets (Q) | 5.00M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.81M | |||
| Current Ratio (Q) | 3.643 | |||
| Book Value Per Share (Q) | $0.23 | |||
| Total Assets (Q) | 5.21M | |||
| Total Current Liabilities (Q) | 1.37M | |||
| Total Debt (Q) | 94.00K | |||
| Total Liabilities (Q) | 1.40M | |||
| Total Common Equity (Q) | 3.81M | |||
| Cash Flow | MBOT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 3.00M | |||
| Cash from Financing (TTM) | 5.10M | |||
| Net Change in Cash (TTM) | -854.00K | |||
| Levered Free Cash Flow (TTM) | -5.96M | |||
| Cash from Operations (TTM) | -8.96M | |||
